Who
Andrew J. Last
Director
Company insider
Files Form 4 as: Director, Insight Molecular Diagnostics; EVP, Chief Operating Officer, Bio-Rad Laboratories; Chief Operating Officer, Precigen; EVP, Chief Operating Officer, Affymetrix.
In numbers
- Trades disclosed
- 147
- Buys
- 7
- Sells
- 3
- Bought
- $184K
- Sold
- $4.0M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 19 Aug 2010
- Last trade
- 1 Jul 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 6 Jul 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code F | $44K7,700 at $5.69 | filing |
| 1 Jul 2026filed 6 Jul 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code F | $44K7,700 at $5.69 | filing |
| 11 Jun 2026filed 15 Jun 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code A | —26,943 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code A | —26,943 at $0.00 | filing |
| 1 Jul 2025filed 3 Jul 2025 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 6 Sep 2024filed 10 Sep 2024 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 6 Sep 2024filed 10 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | $898K3,000 at $299.24 | filing |
| 6 Sep 2024filed 10 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Sold | $990K3,000 at $329.94 | filing |
| 2 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —903 at $0.00 | filing |
| 2 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | —903 at $0.00 | filing |
| 2 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code F | $154K458 at $337.32 | filing |
| 1 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —1,252 at $0.00 | filing |
| 1 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —867 at $0.00 | filing |
| 1 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —633 at $0.00 | filing |
| 1 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | —1,252 at $0.00 | filing |
| 1 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code F | $214K635 at $337.32 | filing |
| 1 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | —867 at $0.00 | filing |
| 1 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code F | $148K440 at $337.32 | filing |
| 1 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | —633 at $0.00 | filing |
| 1 Sep 2024filed 4 Sep 2024 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code F | $108K321 at $337.32 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) versus Oncocyte (NASDAQ:IMDX) Head to Head ComparisonIMDX · dailypolitical.com · 21 Oct 2026Head to Head Comparison: Bio-Rad Laboratories (NYSE:BIO) versus Medpace (NASDAQ:MEDP)BIO · themarketsdaily.com · 20 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyIMDX · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Andrew J. Last; 3 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.